MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2025 International Congress

    Smartphone-based digital assessments in the LUMA trial of BIIB122 for early-stage Parkinson’s disease

    R. Llorens Arenas, J. Edgerton, E. Bartholomé, S. Belachew, M. Gifford, J. Guo, B. Hersh, D. Jennings, C. Kanzler, E. Koca, M. Pang, O. Reyes, C. Shen, M. Wald, N. Woody, C. Mazzá (Cambridge, USA)

    Objective: To evaluate the sensitivity of routine smartphone-based performance assessments in the free-living environment as part of a randomized clinical trial in Parkinson’s disease (PD).…
  • 2025 International Congress

    Inflammatory profile in LRRK2-associated prodromal and clinical PD:a cross-sectional study

    CC. Fan, JY. Liu, JH. Ma, XL. Liu, P. Chan, SY. Liu (Beijing, China)

    Objective: To investigate the peripheral inflammatory cytokine levels and their associations with clinical severity, dopaminergic presynaptic degeneration in asymptomatic carriers and PD patients with LRRK2 mutation.To investigate…
  • 2025 International Congress

    First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Participants

    L. Smits, Y. Zhang, C. Woodward, S. Aksenov, A. Costa Zaninotto, C. Donnelly, T. Storz, Y. Folami, P. Patel, C. Lubeski, M. Macdougall, K. Kelly, A. Hendricson, S. Korsten, P. Kremer, A. Cacace, I. Conti (Leiden, Netherlands)

    Objective: To evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses (SAD/MAD) of ARV-102, a PROteolysis TArgeting Chimera (PROTAC) leucine-rich…
  • 2025 International Congress

    Rapid Neurologic Decline after Subthalamic Nucleus Deep Brain Stimulation in Leucine-Rich Repeat Kinase 2 Parkinson’s disease (LRRK2-PD)

    T. Haddad, M. Rochman, TW. Liang (Phialdelphia, USA)

    Objective: To describe the clinical outcomes of two unrelated patients with LRRK2-PD who experienced rapid neurologic decline following subthalamic nucleus deep brain stimulation (STN-DBS). Background:…
  • 2025 International Congress

    LRRK2 Pathway Inhibition By NEU-411, a Potent, Selective, CNS-Penetrant LRRK2 Inhibitor In Healthy Participants

    C. Wong, S. Dheerendra, T. Dang, F. Nahab, J. Zheng, S. Savage, Z. Pei, C. Wynne, S. Jackson, L. Desnoyers (South San Francisco, USA)

    Objective: The aim of this work was to evaluate LRRK2 pathway modulation by the potent, selective, CNS-penetrant LRRK2 inhibitor NEU-411 in healthy adults and elderly…
  • 2025 International Congress

    Familial parkinson disease A comparative study between LRRK2 and PINK 1 mutations

    A. Mousli, R. Zouari, Z. Saeid, F. Nabli, A. Rachdi, D. Ben Mohamed, S. Ben Sassi (Tunis, Tunisia)

    Objective: Describe the clinical phenotypes of monogenic forms of PD linked to LRRK2 and PINK1 mutations with a view to a comparative study between the…
  • 2025 International Congress

    LRRK2 antisense oligonucleotide (BIIB094/ION859) impact on cerebrospinal fluid biomarkers in Parkinson’s disease patients

    O. Mabrouk (cambridge, USA)

    Objective: To provide novel fluid biomarker results from REASON – a Phase 1 clinical trial testing a LRRK2 antisense oligonucleotide in both LRRK2-Parkinson’s disease and…
  • 2025 International Congress

    Analysis of LRRK2 Exonic Variants in Parkinson’s Disease in Chinese Population

    ZY. Qi, YM. Sun, J. Wang (Shanghai, China)

    Objective: To investigate the frequency of multiple LRRK2 variants in Parkinson's disease (PD) cohort, and to explore the effect of LRRK2 variants on the occurrence…
  • 2025 International Congress

    Investigating the cellular consequences of the G2385R LRRK2 variant

    P. Lewis, S. Herbst (London, United Kingdom)

    Objective: The objective of this study is to characterise the biochemical and cellular impact of the G2385R coding variant in LRRK2, a risk variant for…
  • 2025 International Congress

    Association of sequence alterations in the promoter region of the RAB7L1 gene with lysosomal hydrolase activity in blood and reduced risk of Parkinson disease

    K. Basharova, A. Bezrukova, K. Senkevich, G. Baydakova, I. Miliukhina, A. Timofeeva, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: The aim of this case-control study was to examine the association between SNPs located in the promoter region of the RAB7L1 gene and Parkinson's…
  • 1
  • 2
  • 3
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley